中医药防治肾纤维化的研究现状及实践

何伟明; 刘不悔; 高坤; 周栋; 盛梅笑; 张露; 江燕; 李正红; 孙伟

中医药防治肾纤维化的研究现状及实践

1.
南京中医药大学附属医院，江苏南京 210029
2.
美国匹兹堡大学医学院，匹兹堡 15106

计量
- 文章访问数: 1262
- HTML全文浏览量: 39
- PDF下载量: 1205
- 被引次数: 0
出版历程
- 收稿日期: 2018-02-01
- 刊出日期: 2018-03-10

Research Progress of Chinese Medicine in the Treatment of Renal Fibrosis

1.
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China
2.
Medical School of University of Pittsburgh, Pittsburgh, 15106, USA

摘要

摘要: 肾纤维化是各种慢性肾脏病进展至终末期肾病的病理基础，可危及生命。其发病机制较为复杂，由多种细胞因子和信号通路共同参与。目前尚无有效治疗药物。近年来基于肾纤维化的中医理论及其分子机制，通过随机多中心临床研究以及体内外基础研究，证实多种中药及其有效成分有延缓肾纤维化的疗效，并明确了作用靶点。继续寻找有效的延缓肾纤维化的中药，证实其疗效，明确作用机制尤为重要。
- 肾间质纤维化 /
- 中医药 /
- 单味中药 /
- 中药复方制剂
Abstract: Renal fibrosis is the pathological basis of the progression of various chronic renal diseases to end-stage renal disease， which is life-threatening. Its pathogenesis is complex and is involved in a variety of cytokines and signaling pathways， and there is no effective therapeutic drug until now. In recent years， on the basis of TCM theory of renal fibrosis and its molecular mechanism， through randomized multicenter clinical study and basic research in vitro and in vivo， our hospital confirmed that a variety of Chinese herbs and their effective components have the effect of delaying renal fibrosis， and we have identified their action target. In a word， we should continue to find effective Chinese medicine that can postpone renal fibrosis， to confirm their curative effect， especially to clear their action mechanism.
- renal interstitial fibrosis /
- Chinese medicine /
- single Chinese medicine /
- Chinese medicine compound preparation

HTML全文

参考文献(59)

[1]	HALLAN SI， OVREHUS MA， ROMUNDSTAD S， et al. Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway[J]. Kidney Int， 2016， 90(3): 665-673.〖ZK)〗
[2]	DECLVES AE， SHARMA K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD[J]. Nat Rev Nephrol， 2014， 10(5): 257-267.〖ZK)〗
[3]	SZETO HH. Pharmacologic approaches to improve mitochondrial function in AKI and CKD[J]. J Am Soc Nephrol， 2017， 28(10): 2856-2865.〖ZK)〗
[4]	WANG HW， SHI L， XU YP， et al. Hesperetin alleviates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro[J]. Exp Ther Med， 2017， 14(4): 3713-3719.〖ZK)〗
[5]	ELLISON DH. Treatment of disorders of Sodium balance in chronic kidney disease[J]. Adv Chronic Kidney Dis， 2017， 24(5): 332-341.〖ZK)〗
[6]	邹燕勤，王钢．孟河医派临床大家邹云翔论治肾病经验[J]．江苏中医药，2016，48（6）：1-5．〖ZK)〗
[7]	王钢．谈继承发扬邹云翔老师治肾学术思想的过程和心得体会[J]．中国中西医结合肾病杂志，2015（5）：380-385．〖ZK)〗
[8]	王钢，邹燕勤，邹孚庭．一代名医邹云翔为中国中医肾病学发展作出的贡献[J]．中国中西医结合肾病杂志，2016，17（3）：192-196．〖ZK)〗
[9]	周恩超，孙伟，易岚.邹燕勤：和诚精勤于中医肾病事业[N].中国中医药报，2017-3-22（8）.〖ZK)〗
[10]	易岚．邹燕勤治疗慢性肾小球肾炎的经验[J]．江苏中医药，2015，47（12）：11-13．〖ZK)〗
[11]	朱晓雷．邹燕勤教授运用益肾健脾，和络泄浊法治疗慢性肾衰竭的理论及临床研究[D]．南京：南京中医药大学，2016．〖ZK)〗
[12]	许陵冬，王晗.龚丽娟：益肾健脾泄浊治慢性肾衰[N].中国中医药报，2015-2-9（4）.〖ZK)〗
[13]	尤永卿，许陵冬．龚丽娟教授治疗尿酸性肾病经验撷要[J]．河北中医，2016，38（4）：487．〖ZK)〗
[14]	陶兴，许陵冬，龚丽娟．龚丽娟益肾清利法治疗慢性肾炎临床研究[J]．辽宁中医杂志，2014（1）：88．〖ZK)〗
[15]	江燕，何伟明，余承惠．肾炎湿热论[J]．四川中医，2014，32（1）：53．〖ZK)〗
[16]	李华伟．余承惠辨证结合辨病分期治疗特发性膜性肾病经验[J]．贵阳中医学院学报，2017，39（5）：12．〖ZK)〗
[17]	何伟明.余承惠教授中西医结合“治肾”观点[C]//中国中西医结合学会肾脏疾病专业委员会2015年学术年会资料汇编.南宁：中国中西医结合学会肾脏疾病专业委员会，2015：2.〖ZK)〗
[18]	王俊，徐梅昌，邓旭，等．孙伟教授益肾清利活络法治疗慢性肾脏病肾性贫血[J]．吉林中医药，2017，37（3）：226．〖ZK)〗
[19]	徐秀琴．孙伟运用扶正祛邪药对治疗慢性肾脏病经验[J]．山东中医杂志，2016，35（1）：51〖ZK)〗
[20]	沙鑫，孙伟．孙伟运用泄浊解毒法治疗慢性肾脏病阐微[J]．山东中医药大学学报，2017（2）：131．〖ZK)〗
[21]	余斐，孙伟．孙伟在激素不同阶段辨证治疗肾病综合征经验[J]．中华中医药杂志，2016（2）：539．〖ZK)〗
[22]	LEE SY， KIM SI， CHOI ME. Therapeutic targets for treating fibrotic kidney diseases[J]. Transl Res， 2015， 165(4): 512-530.〖ZK)〗
[23]	ZHOU J， ZHONG J， LIN S， et al. Inhibition of PTEN activity aggravates post renal fibrosis in mice with ischemia Reperfusion-Induced acute kidney injury[J]. Cell Physiol Biochem， 2017， 43(5): 1841-1854.〖ZK)〗
[24]	YANG R， YUAN BC， MA YS， et al. The anti-inflammatory activity of licorice， a widely used Chinese herb[J]. Pharm Biol， 2017， 55(1): 5-18.〖ZK)〗
[25]	BAO J， DING R， ZOU L， et al. Forsythiae fructus inhibits B16 melanoma growth involving MAPKs/Nrf2/HO-1 mediated Anti-Oxidation and Anti-Inflammation[J]. Am J Chin Med， 2016， 44(5): 1043-1061.〖ZK)〗
[26]	YE C， YU X， ZENG J， et al. Effects of baicalein on proliferation， apoptosis， migration and invasion of Ewing's sarcoma cells[J]. Int J Oncol， 2017: 29039470.〖ZK)〗
[27]	ZHANG S， WANG D， WANG X， et al. Aqueous extract of Bai-Hu-Tang， a classical Chinese herb formula， prevents excessive immune response and liver injury induced by LPS in rabbits[J]. J Ethnopharmacol， 2013， 149(1): 321-327.〖ZK)〗
[28]	SHIMA H， SASAKI K， SUZUKI T， et al. A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-α and TGF-β1 pathways[J]. Sci Rep， 2017， 7(1): 1884.〖ZK)〗
[29]	QUIROGA B， ARROYO D， DE ARRIBA G. Present and future in the treatment of diabetic kidney disease[J]. J Diabetes Res， 2015: 801348.〖ZK)〗
[30]	OH YJ， AN JN， KIM CT， et al. Circulating tumor necrosis factorα receptors predict the outcomes of human IgA nephropathy: a prospective cohort study[J]. PLoS One， 2015， 10(7): e0132826.〖ZK)〗
[31]	YUAN JL， TAO YY， WANG QL， et al. Fuzheng huayu formula prevents rat renal interstitial fibrosis induced by HgCl₂ via antioxidative stress and down-regulation of nuclear factor-kappa B activity[J]. Chin J Integr Med， 2017， 23(8): 598-604.〖ZK)〗
[32]	HALLER ST， KUMARASAMY S， FOLT DA， et al. Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria， Independent of blood pressure[J]. Kidney Int， 2017， 91(2): 365-374.〖ZK)〗
[33]	SANZ AB， RUIZ-ANDRES O， SANCHEZ-NINO MD， et al. Out of the TWEAK light: elucidating the role of Fn14 and TWEAK in acute kidney injury[J]. Semin Nephrol， 2016， 36(3): 189-198.〖ZK)〗
[34]	RUIZ-ANDRES O， SUAREZ-ALVAREZ B， SNCHEZ-RAMOS C， et al. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury[J]. Kidney Int， 2016， 89(2): 399-410.〖ZK)〗
[35]	GOMEZ IG， ROACH AM， NAKAGAWA N， et al. TWEAK-Fn14 signaling activates myofibroblasts to drive progression of fibrotic kidney disease[J]. J Am Soc Nephrol， 2016， 27(12): 3639-3652.〖ZK)〗
[36]	BIJKERK R， DE BRUIN RG， VAN SOLINGEN C， et al. Silencing of microRNA-132 reduces renal fibrosis byselectively inhibiting myofibroblast proliferation[J]. Kidney Int， 2016， 89(6): 1268-1280.〖ZK)〗
[37]	TU Y， SUN W， WAN YG， et al. Dahuang Fuzi decoction ameliorates tubular epithelial apoptosis and renal damage via inhibiting TGF-β1-JNK signaling pathway activation in vivo[J]. J Ethnopharmacol， 2014， 156: 115-124.〖ZK)〗
[38]	ZHANG H， SONG Y， LI Z， et al. Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats[J]. Am J Surg， 2016， 211(6): 1143-1152.〖ZK)〗
[39]	YANG Y， NIAN H， TANG X， et al. Effects of the combined Herba Epimedii and Fructus Ligustri Lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats[J]. J Ethnopharmacol， 2017， 201: 91-99.〖ZK)〗
[40]	ANORGA S， OVERSTREET JM， FALKE LL， et al. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype[J]. FASEB J， 2018: fj201700722R.〖ZK)〗
[41]	RAYEGO-MATEOS S， MORGADO-PASCUAL JL， RODRIGUES-DIEZ RR， et al. Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation[J]. J Pathol， 2018， 244(2): 227-241.〖ZK)〗
[42]	刘湘丹. 补肾通络方药效物质基础及基于TGF-β1/CTGF因子的作用机制研究 [D]. 长沙：湖南中医药大学，2015.〖ZK)〗
[43]	LEE SY， KIM SI， CHOI ME. Therapeutic targets for treating fibrotic kidney diseases[J]. Transl Res， 2015， 165(4): 512-530.〖ZK)〗
[44]	NAMGUNG S， YOON JJ， YOON CS， et al. Prunella vulgaris Attenuates Diabetic Renal Injury by Suppressing Glomerular Fibrosis and Inflammation[J]. Am J Chin Med， 2017， 45(3): 475-495.〖ZK)〗
[45]	WANG N， DENG Y， LIU A， et al. Novel mechanism of the Pericyte-Myofibroblast transition in renal interstitial fibrosis: core fucosylation regulation[J]. Sci Rep， 2017， 7(1): 16914.〖ZK)〗
[46]	ISHII Y， HAMASHIMA T， YAMAMOTO S， et al. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor[J]. Pathol Int， 2017， 67(5): 235-246.〖ZK)〗
[47]	OSTENDORF T， BOOR P， VAN ROEYEN CR， et al. Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis[J]. Kidney Int Suppl， 2014， 4(1): 65-69.〖ZK)〗
[48]	BAI J， GENG W， MEI Y， et al. Effect of huaier on the proliferation of mesangial cells in Anti-Thy-1 nephritis[J]. Cell Physiol Biochem， 2017， 42(6): 2441-2452.〖ZK)〗
[49]	HAN JW， SHIM DW， SHIN WY， et al. Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation[J]. Int J Mol Sci， 2015， 16(4): 8102-8109.〖ZK)〗
[50]	ZHANG CY， ZHU JY， YE Y， et al. Erhuang formula ameliorates renal damage in adenine-induced chronic renal failure rats via inhibiting inflammatory and fibrotic responses[J]. Biomed Pharmacother， 2017， 95: 520-528.〖ZK)〗
[51]	ZHOU X， SUN X， GONG X， et al. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro[J]. Int Immunopharmacol， 2017， 42: 18-24.〖ZK)〗
[52]	FALKE LL， VAN VUUREN SH， KAZAZI-HYSENI F， et al. Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres[J]. Biomaterials， 2015， 42: 151-160.〖ZK)〗
[53]	LI XY， WANG SS， HAN Z， et al. Triptolide restores autophagy to alleviate diabetic renal fibrosis through the miR-141-3p/PTEN/Akt/mTOR pathway[J]. Mol Ther Nucleic Acids， 2017， 9: 48-56.〖ZK)〗
[54]	GAO K， CHI Y， ZHANG X， et al. A novel TXNIP-based mechanism for Cx43-mediated regulation of oxidative drug injury[J]. J Cell Mol Med， 2015， 19(10): 2469-2480.〖ZK)〗
[55]	YAN Q， GAO K， CHI Y， et al. NADPH oxidase-mediated upregulation of connexin43 contributes to podocyte injury[J]. Free Radic Biol Med， 2012， 53(6): 1286-1297.〖ZK)〗
[56]	LIU HF， LIU H， LV LL， et al. CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro[J]. Acta Pharmacol Sin， 2017: 28858296.〖ZK)〗
[57]	SHI J， LI Q， SHENG M， et al. The role of TLR4 in M1 Macrophage-Induced Epithelial-Mesenchymal transition of peritoneal mesothelial cells[J]. Cell Physiol Biochem， 2016， 40(6): 1538-1548.〖ZK)〗
[58]	ZHANG L， LI Z， HE W， et al. Effects of astragaloside Ⅳ against the TGF-β1-Induced Epithelial-to-Mesenchymal transition in peritoneal mesothelial cells by promoting Smad 7 expression[J]. Cell Physiol Biochem， 2015， 37(1): 43-54.〖ZK)〗
[59]	Li ZH，Zhang L，He WM，et al. Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemo attractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis [J]. J Int Mol Sci，2014，15：12959.〖ZK)〗